VBI Vaccines, Inc. - Ordinary Shares (VBIV): Price and Financial Metrics


VBI Vaccines, Inc. - Ordinary Shares (VBIV): $0.58

-0.01 (-2.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VBIV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VBIV POWR Grades

  • Growth is the dimension where VBIV ranks best; there it ranks ahead of 43.22% of US stocks.
  • VBIV's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • VBIV's current lowest rank is in the Quality metric (where it is better than 3.05% of US stocks).

VBIV Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for VBIV is 0.01 -- better than just 8.21% of US stocks.
  • With a price/sales ratio of 203.04, VBI VACCINES INC has a higher such ratio than 98.64% of stocks in our set.
  • With a year-over-year growth in debt of 82.41%, VBI VACCINES INC's debt growth rate surpasses 86.09% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to VBI VACCINES INC, a group of peers worth examining would be DDD, RCEL, OM, CASI, and UPWK.
  • Visit VBIV's SEC page to see the company's official filings. To visit the company's web site, go to www.vbivaccines.com.

VBIV Valuation Summary

  • VBIV's price/sales ratio is 278.6; this is 14563.16% higher than that of the median Healthcare stock.
  • Over the past 243 months, VBIV's price/sales ratio has gone down 1618.1.

Below are key valuation metrics over time for VBIV.

Stock Date P/S P/B P/E EV/EBIT
VBIV 2022-11-01 278.6 1.7 -1.8 -1.4
VBIV 2022-10-31 281.7 1.8 -1.8 -1.4
VBIV 2022-10-28 284.1 1.8 -1.8 -1.4
VBIV 2022-10-27 266.1 1.7 -1.7 -1.3
VBIV 2022-10-26 277.4 1.7 -1.8 -1.4
VBIV 2022-10-25 271.2 1.7 -1.8 -1.3

VBIV Growth Metrics

    The 5 year revenue growth rate now stands at 315.33%.
  • The 5 year cash and equivalents growth rate now stands at 10.91%.
  • Its 2 year cash and equivalents growth rate is now at 183.04%.
Over the past 33 months, VBIV's revenue has gone down $1,351,000.

The table below shows VBIV's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.87 -73.165 -110.945
2022-06-30 0.66 -59.921 -101.583
2022-03-31 0.456 -53.189 -73.36
2021-12-31 0.631 -39.908 -69.753
2021-09-30 0.714 -37.887 -66.332
2021-06-30 0.905 -48.957 -63.482

VBIV's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VBIV has a Quality Grade of F, ranking ahead of 2.02% of graded US stocks.
  • VBIV's asset turnover comes in at 0.004 -- ranking 418th of 681 Pharmaceutical Products stocks.
  • NOVN, CKPT, and ARWR are the stocks whose asset turnover ratios are most correlated with VBIV.

The table below shows VBIV's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.004 -9.583 -1.419
2021-03-31 0.005 -8.508 -1.124
2020-12-31 0.006 -7.641 -1.240
2020-09-30 0.010 -5.345 -1.736
2020-06-30 0.014 -4.054 -3.663
2020-03-31 0.019 -3.171 -175.420

VBIV Stock Price Chart Interactive Chart >

Price chart for VBIV

VBIV Price/Volume Stats

Current price $0.58 52-week high $3.42
Prev. close $0.59 52-week low $0.55
Day low $0.56 Volume 314,300
Day high $0.60 Avg. volume 1,832,683
50-day MA $0.68 Dividend yield N/A
200-day MA $1.03 Market Cap 149.27M

VBI Vaccines, Inc. - Ordinary Shares (VBIV) Company Bio


VBI Vaccines Inc. develops vaccine candidates and novel technology platforms in Israel and internationally. It develops products based on eVLP, a platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccines platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.


VBIV Latest News Stream


Event/Time News Detail
Loading, please wait...

VBIV Latest Social Stream


Loading social stream, please wait...

View Full VBIV Social Stream

Latest VBIV News From Around the Web

Below are the latest news stories about VBI VACCINES INC that investors may wish to consider to help them evaluate VBIV as an investment opportunity.

VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting

CAMBRIDGE, Mass., November 22, 2022--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that additional biomarker data from the Phase 1/2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), were presented at the 27th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), on Friday, November 18, 2022.

Yahoo | November 22, 2022

VBI Vaccines to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., November 14, 2022--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that members of the management team will participate in analyst-led fireside chats at the following investor conferences:

Yahoo | November 14, 2022

VBI Vaccines Announces Presentation of Data from Ongoing Phase 2a Study of VBI-1901 at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting

CAMBRIDGE, Mass., November 11, 2022--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that its abstract highlighting data from the ongoing Phase 2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), was accepted for poster presentation at the 27th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO),

Yahoo | November 11, 2022

VBI Vaccines, Inc. (VBIV) Reports Q3 Loss, Misses Revenue Estimates

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -12.50% and 75.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 10, 2022

VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., November 10, 2022--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced financial results for the third quarter ended September 30, 2022, and provided a corporate update.

Yahoo | November 10, 2022

Read More 'VBIV' Stories Here

VBIV Price Returns

1-mo -14.77%
3-mo -38.36%
6-mo N/A
1-year -79.14%
3-year -31.44%
5-year -87.74%
YTD -75.21%
2021 -14.91%
2020 99.28%
2019 -13.75%
2018 -62.53%
2017 37.74%

Continue Researching VBIV

Here are a few links from around the web to help you further your research on VBI Vaccines Inc's stock as an investment opportunity:

VBI Vaccines Inc (VBIV) Stock Price | Nasdaq
VBI Vaccines Inc (VBIV) Stock Quote, History and News - Yahoo Finance
VBI Vaccines Inc (VBIV) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6853 seconds.